AI assistant
Altimmune, Inc. — Director's Dealing 2017
Oct 18, 2017
33207_dirs_2017-10-17_8e377dad-6030-4bb1-b34e-e08339f6b8e6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Altimmune, Inc. (ALT)
CIK: 0001326190
Period of Report: 2017-10-13
Reporting Person: Hodges Philip (Director)
Reporting Person: Redmont VAXN Capital Holdings, LLC (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-10-17 | Common Stock, par value $0.0001 | J | 1278471 | — | Disposed | 0 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-10-13 | Stock Options (option to buy) | $2.50 | A | 20000 | Acquired | 2027-10-13 | Common Stock, par value $0.0001 (20000) | Direct |
Footnotes
F1: Redmont VAXN Capital Holdings, LLC, a Delaware limited liability company ("Redmont VAXN") distributed to its members, pro rata and without consideration, 1,278,471 shares of the Issuer's common stock.
F2: Consists of shares of Common Stock held by Redmont VAXN. Philip Hodges has sole voting and dispositive control with respect to all securities held by Redmont VAXN. Philip Hodges disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F3: Held by Philip Hodges.